Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer

International Journal of Oncology

Volumn 40, Issue 1, 2012, Pages 217-226

  Miyaki, Yuichiro ^a   Suzuki, Koichi ^b   Koizumi, Kei ^a   Kato, Takaharu ^b   Saito, Masaki ^b   Kamiyama, Hidenori ^b   Maeda, Takafumi ^b   Shibata, Kiyoshi ^a   Shiya, Norihiko ^a   Konishi, Fumio ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Colorectal cancer; Drug resistance; Glucocorticoid induced protein coding gene; Promoter methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BIOLOGICAL MARKER; CAMPTOTHECIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; SMALL INTERFERING RNA;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER PATIENT; CANCER RESISTANCE; COLON CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DEXI GENE; EPIGENETICS; FEMALE; GENE; GENE EXPRESSION; GENE INDUCTION; GENE SILENCING; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; METHYLATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CACO-2 CELLS; CAMPTOTHECIN; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA METHYLATION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84455171368     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1189     Document Type: Article

References (37)

1. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000. (Pubitemid 30644117)
2. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000. (Pubitemid 30162806)
3. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004. (Pubitemid 41095110)
4. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
5. Liu LF, Desai SD, Li TK, Mao Y, Sun M and Sim SP: Mechanism of action of camptothecin. Ann NY Acad Sci 922: 1-10, 2000. (Pubitemid 32050237)
6. Tournigand C, Andre T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004. (Pubitemid 41095086)
7. Xu Y and Villalona-Calero MA: Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13: 1841-1851, 2002. (Pubitemid 36040772)
8. Huang TT, Wuerzberger-Davis SM, Seufzer BJ, et al.: NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J Biol Chem 275: 9501-9509, 2000. (Pubitemid 30185179)
9. Frigola J, Sole X, Paz MF, et al.: Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Hum Mol Genet 14: 319-326, 2005.
10. Yamamoto F, Yamamoto M, Soto JL, et al.: Notl-Msell methylation- sensitive amplied fragment length polymorhism for DNA methylation analysis of human cancers. Electrophoresis 22: 1946-1956, 2001. (Pubitemid 32621922)
11. Suzuki K, Suzuki I, Leodolter A, et al.: Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell 9: 199-207, 2006. (Pubitemid 43357946)
12. Edgar AJ, Birks EJ, Yacoub MH and Polak JM: Cloning of dexamethasone- induced transcript: a novel glucocorticoid-induced gene that is upregulated in emphysema. Am J Respir Cell Mol Biol 25: 119-124, 2001. (Pubitemid 32682714)
13. O'Shea EK, Rutkowski R and Kim PS: Evidence that the leucine zipper is a coiled coil. Science 243: 538-542, 1989. (Pubitemid 19048755)
14. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996. (Pubitemid 26296693)
15. Collado M and Serrano M: The power and the promise of oncogene- induced senescence markers. Nat Rev Cancer 6: 472-476, 2006.
16. Issa JP: DNA methylation as a therapeutic target in cancer. Clin Cancer Res 13: 1634-1637, 2007.
17. K aminskas E, Farrell A, Abraham S, et al.: Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11: 3604-3608, 2005.
18. Goffin J and Eisenhauer E: DNA methyltransferase inhibitorsstate of the art. Ann Oncol 13: 1699-1716, 2002.
19. Moertel CG, Schutt AJ, Reitemeier RJ and Hahn RG: Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 649-652, 1972.
20. Abele R, Clavel M, Dodion P, et al.: The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol 23: 1921-1924, 1987. (Pubitemid 18013335)
21. Appleton K, Mackay HJ, Judson I, et al.: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25: 4603-4609, 2007. (Pubitemid 350035319)
22. Ding L, Qiu L, Zhang J and Guo B: Camptothecin-induced cell proliferation inhibition and apoptosis enhanced by DNA methyltransferase inhibitor, 5-aza-2′-deoxycytidine. Biol Pharm Bull 32: 1105-1108, 2009.
23. Ishiguro M, Iida S, Uetake H, et al.: Effect of combined therapy with low-dose 5-aza-2′-deoxycytidine and irinotecan on colon cancer cell line HCT-15. Ann Surg Oncol 14: 1752-1762, 2007. (Pubitemid 46790993)
24. K iziltepe T, Hideshima T, Catley L, et al.: 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 6: 1718-1727, 2007.
25. Mirza S, Sharma G, Pandya P and Ralhan R: Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents. Mol Cell Biochem 342: 101-109, 2010.
26. Orta ML, Mateos S and Cortes F: DNA demethylation protects from cleavable complex stabilization and DNA strand breakage induced by the topoisomerase type I inhibitor camptothecin. Mutagenesis 24: 237-244, 2009.
27. Shang D, Ito N, Kamoto T and Ogawa O: Demethylating agent 5-aza-2′-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel. Urology 69: 1007-1012, 2007. (Pubitemid 46670259)
28. Zhang X, Yashiro M, Ohira M, Ren J and Hirakawa K: Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma. Cancer Sci 97: 938-944, 2006. (Pubitemid 44151277)
29. Crea F, Giovannetti E, Cortesi F, et al.: Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Mol Cancer Ther 8: 1964-1973, 2009.
30. Adams GP and Weiner LM: Monoclonal antibody therapy of cancer. Nature Biotechnology 23: 1147-1157, 2005. (Pubitemid 41486396)
31. Amado RG, Wolf M, Peeters M, et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
32. Lievre A, Bachet JB, Le Corre D, et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
33. Zody MC, Garber M, Sharpe T, et al.: Analysis of the DNA sequence and duplication history of human chromosome 15. Nature 440: 671-675, 2006.
34. Christian SL, Fantes JA, Mewborn SK, Huang B and Ledbetter DH: Large genomic duplicons map to sites of instability in the Prader-Willi/Angelman syndrome chromosome region (15q11-q13). Hum Mol Genet 8: 1025-1037, 1999. (Pubitemid 29250890)
35. Falls JG, Pulford DJ, Wylie AA and Jirtle RL: Genomic imprinting: implications for human disease. Am J Pathol 154: 635-647, 1999. (Pubitemid 29122582)
36. Christian SL, Bhatt NK, Martin SA, et al.: Integrated YAC contig map of the Prader-Willi/Angelman region on chromosome 15q11-q13 with average STS spacing of 35 kb. Genome Res 8: 146-157, 1998. (Pubitemid 128724401)
37. Martin J, Han C, Gordon LA, et al.: The sequence and analysis of duplication-rich human chromosome 16. Nature 432: 988-994, 2004.